Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Kotsanis | M | - | 10 years | |
| Brendan Brown | M | - |
Paranta Biosciences Ltd.
 Paranta Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Paranta Biosciences Ltd. engages in the research and development of novel biotherapeutic. t develops PB01 (recombinant human follistatin-288) for the treatment of fibrotic and inflammatory diseases. The company was founded in 2011 and is headquartered in Richmond, Australia. | - |
| Timothy Oldham | M | - | 11 years | |
| David M. de Kretser | M | - |
Paranta Biosciences Ltd.
Paranta Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Paranta Biosciences Ltd. engages in the research and development of novel biotherapeutic. t develops PB01 (recombinant human follistatin-288) for the treatment of fibrotic and inflammatory diseases. The company was founded in 2011 and is headquartered in Richmond, Australia. | - |
| John W. Raff | M | 74 |
Paranta Biosciences Ltd.
Paranta Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Paranta Biosciences Ltd. engages in the research and development of novel biotherapeutic. t develops PB01 (recombinant human follistatin-288) for the treatment of fibrotic and inflammatory diseases. The company was founded in 2011 and is headquartered in Richmond, Australia. | - |
| Peter Hodgson | M | - |
Paranta Biosciences Ltd.
Paranta Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Paranta Biosciences Ltd. engages in the research and development of novel biotherapeutic. t develops PB01 (recombinant human follistatin-288) for the treatment of fibrotic and inflammatory diseases. The company was founded in 2011 and is headquartered in Richmond, Australia. | 8 years |
| Felicia Colagrande | F | - | 9 years | |
| Austin S. E. Miller | M | - |
Paranta Biosciences Ltd.
Paranta Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Paranta Biosciences Ltd. engages in the research and development of novel biotherapeutic. t develops PB01 (recombinant human follistatin-288) for the treatment of fibrotic and inflammatory diseases. The company was founded in 2011 and is headquartered in Richmond, Australia. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jon Pilcher | M | 58 | 11 years | |
| Clive Blower | M | - | 7 years | |
| Tony di Pietro | M | - | 10 years | |
| Sharon Papworth | F | - | 2 years | |
| Henry Kenneth Windle | M | - | 11 years | |
| Richard Treagus | M | 58 | 6 years | |
| Jeffery Parncutt | M | 73 | 4 years | |
| Nina Webster | M | - | 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Australia | 16 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Ross Barrow
- Personal Network
